Profile data is unavailable for this security.
About the company
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206. The tebipenem HBr is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. SPR206 is a direct acting intravenous (IV)-administered product candidate being developed as an option to treat MDR Gram-negative bacterial infections in the hospital setting.
- Revenue in USD (TTM)103.78m
- Net income in USD22.81m
- Incorporated2013
- Employees46.00
- LocationSpero Therapeutics Inc675 Massachusetts Ave Ste 14CAMBRIDGE 02139-3309United StatesUSA
- Phone+1 (857) 242-1600
- Fax+1 (302) 655-5049
- Websitehttps://sperotherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chimerix Inc | 41.00k | -82.59m | 85.41m | 72.00 | -- | 0.4906 | -- | 2,083.13 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| MDxHealth SA - ADR | -100.00bn | -100.00bn | 85.68m | 258.00 | -- | 11.89 | -- | -- | -- | -- | -- | 0.2641 | -- | -- | -- | -- | -- | -51.62 | -- | -64.72 | -- | 50.90 | -- | -117.64 | 1.81 | -- | 0.8513 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| BioXcel Therapeutics Inc | 1.38m | -179.05m | 85.93m | 74.00 | -- | -- | -- | 62.27 | -6.16 | -6.16 | 0.0474 | -1.89 | 0.0099 | 0.6343 | 8.65 | 18,648.65 | -128.10 | -74.57 | -163.23 | -84.06 | 8.62 | -- | -12,974.86 | -32,300.74 | 2.57 | -21.87 | 2.28 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Beyondspring Inc | 1.75m | -21.03m | 87.58m | 35.00 | -- | -- | -- | 50.02 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Connect Biopharma Holdings Ltd (ADR) | 0.00 | -59.50m | 87.61m | 81.00 | -- | 0.905 | -- | -- | -1.08 | -1.08 | 0.00 | 1.76 | -- | -- | -- | 0.00 | -- | -66.24 | -- | -71.36 | -- | -- | -- | -- | -- | -- | 0.0046 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
| Jaguar Health Inc | 9.76m | -41.30m | 87.84m | 49.00 | -- | 4.71 | -- | 9.00 | -3.64 | -3.64 | 0.4239 | 0.0676 | 0.1988 | 0.2513 | 5.08 | 199,204.10 | -85.33 | -95.29 | -153.34 | -163.54 | 79.13 | 67.28 | -429.27 | -522.28 | 1.34 | -2.95 | 0.8799 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| Spero Therapeutics Inc | 103.78m | 22.81m | 87.85m | 46.00 | 4.02 | 0.8082 | 3.79 | 0.8465 | 0.4055 | 0.4055 | 1.96 | 2.02 | 0.6757 | -- | 4.01 | 2,256,087.00 | 14.85 | -35.52 | 18.36 | -41.75 | -- | -- | 21.98 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -31.05m | 87.99m | 43.00 | -- | 6.44 | -- | -- | -0.6825 | -0.6825 | 0.00 | 0.2529 | 0.00 | -- | -- | -- | -84.76 | -70.19 | -97.55 | -78.31 | -- | -- | -- | -15,434.15 | 0.7822 | -42.08 | 0.4717 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -39.26m | 89.34m | 10.00 | -- | 15.62 | -- | -- | -1.66 | -1.66 | 0.00 | 0.2048 | 0.00 | -- | -- | -- | -184.22 | -- | -404.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 1.00m | -59.69m | 89.82m | 47.00 | -- | 3.37 | -- | 89.82 | -1.39 | -1.39 | 0.0233 | 0.5009 | 0.0134 | -- | 0.3949 | 21,276.60 | -79.73 | -48.44 | -87.55 | -51.56 | -- | -- | -5,968.50 | -1,267.25 | -- | -- | 0.748 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Armata Pharmaceuticals Inc | 4.53m | -69.05m | 90.01m | 66.00 | -- | -- | -- | 19.87 | -1.91 | -1.91 | 0.1255 | -0.8877 | 0.0466 | -- | -- | 68,621.21 | -71.11 | -59.78 | -90.34 | -72.70 | -- | -- | -1,524.51 | -1,113.72 | -- | -1.68 | 1.64 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Allovir Inc | 0.00 | -190.42m | 91.70m | 112.00 | -- | -- | -- | -- | -1.83 | -1.83 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -52.85 | -- | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | -- | -- | -- | -- | -12.87 | -- | -- | -- |
Data as of May 06 2024. Currency figures normalised to Spero Therapeutics Inc's reporting currency: US Dollar USD
19.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Anson Funds Management LPas of 31 Dec 2023 | 4.30m | 7.98% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.63m | 3.03% |
| Adar1 Capital Management LLCas of 31 Dec 2023 | 1.07m | 1.98% |
| Murchinson Ltd.as of 31 Dec 2023 | 862.70k | 1.60% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 547.47k | 1.02% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 469.64k | 0.87% |
| Geode Capital Management LLCas of 31 Dec 2023 | 412.71k | 0.77% |
| Columbia Management Investment Advisers LLCas of 31 Dec 2023 | 402.96k | 0.75% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 343.86k | 0.64% |
| AWM Investment Co., Inc.as of 31 Dec 2023 | 333.40k | 0.62% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
